A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis.
J Eur Acad Dermatol Venereol
; 36(2): e111-e113, 2022 Feb.
Article
in English
| MEDLINE | ID: covidwho-1402940
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Psoriasis
/
Antibodies, Monoclonal
Type of study:
Experimental Studies
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Eur Acad Dermatol Venereol
Journal subject:
Dermatology
/
Sexually Transmitted Diseases
Year:
2022
Document Type:
Article
Affiliation country:
Jdv.17656
Similar
MEDLINE
...
LILACS
LIS